1997
DOI: 10.1086/514057
|View full text |Cite
|
Sign up to set email alerts
|

Anti‐Human Immunodeficiency Virus (HIV) Activity, Safety, and Pharmacokinetics of Adefovir Dipivoxil (9‐[2‐(bis‐pivaloyloxymethyl)‐phosphonylmethoxyethyl]adenine) in HIV‐Infected Patients

Abstract: A randomized, double-blind, placebo-controlled, dose-escalation study of adefovir dipivoxil, an oral prodrug of adefovir, was conducted in 36 human immunodeficiency virus (HIV)-infected subjects to evaluate its anti-HIV activity, safety, and pharmacokinetics. Subjects received placebo or one of three dosages of adefovir dipivoxil daily for 14 days. Median decreases in serum p24 antigen of 31% (P = .02), 25% (P = .31), and 30% (P = .01) occurred in each drug-treated group, respectively, compared with an increas… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
29
0

Year Published

1997
1997
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 92 publications
(31 citation statements)
references
References 25 publications
1
29
0
Order By: Relevance
“…Adefovir dipivoxil was readily absorbed after oral administration to mice [13], rats [15], dogs [16] and man [17]. Adefovir dipivoxil and its monoester (mono-POM PMEA) were not observed in plasma, suggesting rapid hydrolysis of the prodrug to adefovir (PMEA) before reaching the systemic circulation.…”
Section: Discussionmentioning
confidence: 99%
“…Adefovir dipivoxil was readily absorbed after oral administration to mice [13], rats [15], dogs [16] and man [17]. Adefovir dipivoxil and its monoester (mono-POM PMEA) were not observed in plasma, suggesting rapid hydrolysis of the prodrug to adefovir (PMEA) before reaching the systemic circulation.…”
Section: Discussionmentioning
confidence: 99%
“…at 3 dose lev els (125, 250 or 500 mg once daily), was found to effect a significant decrease in serum p24 antigen and HIV RNA copies. Adefovir dipovoxil was best tolerated at the lowest dose (125 mg daily) studied, and its anti-HIV activity was already evident after 8 days of dosing [53]. In another randomized, double-blind, placebo-controlled study [54], adefovir dipixovil.…”
Section: Rna Virus Infectionsmentioning
confidence: 97%
“…The first case of an hypopharyngeal/esophageal papilloma (due to HPV type 16) that showed complete regression under topical cidofovir therapy was reported three years ago [47], In a randomized, double-blind, placebo-controlled, dose-escala tion study [53], bis(POM)-PMEA (adefovir dipivoxil). at 3 dose lev els (125, 250 or 500 mg once daily), was found to effect a significant decrease in serum p24 antigen and HIV RNA copies.…”
Section: Rna Virus Infectionsmentioning
confidence: 99%
“…However, although adefovir shows significant in vitro antiviral activity against poxviruses, its efficacy as a therapeutic agent for smallpox is currently uncertain. In addition to its activity against VACV replication in tissue culture, it has a good oral availability and has been approved for treatment of Hepatitis B [45], making it a serious candidate. This compound needs to be evaluated further for its activity against monkeypox and variola viruses before its real potential is known [46].…”
Section: Introductionmentioning
confidence: 99%